Mobia Medical reported strong Q3 2026 financial results, with revenue increasing by 73% and gross profit by 81%. The company also raised its full-year 2026 revenue guidance, indicating robust performance and positive future outlook, despite a significant increase in operating expenses.
Mobia Medical's Q3 2026 earnings report shows a significant 73% year-over-year revenue increase to $15.6 million, driven by the Vivistim Paired VNS System. This strong performance led the company to raise its full-year revenue guidance from $54.0-$56.0 million to $57.0-$57.5 million, signaling robust growth and positive momentum. While operating expenses rose by 71% to $31.5 million due to commercial investments, the substantial revenue and gross profit growth (81%) suggest these investments are yielding results. This news is a short-term positive catalyst for MMED, indicating strong operational execution and potential for continued growth, offering an opportunity for traders to consider long positions based on the improved outlook.